FILANA THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FILANA THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2013 | $35.24M | Mar 3, 2016 |
| FY2015 | Sep 30, 2013 | $1.96M | Mar 3, 2016 |
| FY2015 | Jun 30, 2013 | $1.96M | Mar 3, 2016 |
| FY2015 | Mar 31, 2013 | $1.96M | Mar 3, 2016 |
| FY2014 | Dec 31, 2012 | $2.47M | Feb 18, 2015 |
| FY2014 | Sep 30, 2012 | $2.73M | Feb 18, 2015 |
| FY2014 | Jun 30, 2012 | $2.72M | Feb 18, 2015 |
| FY2014 | Mar 31, 2012 | $2.97M | Feb 18, 2015 |
| FY2012 | Dec 31, 2011 | $2.75M | Feb 8, 2013 |
| FY2012 | Sep 30, 2011 | $2.75M | Feb 8, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($90.97M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($24.34M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($97.22M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($76.25M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($32.39M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($6.33M) | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | ($4.63M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($6.56M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($11.91M) | Mar 29, 2019 |
| FY2016 | Dec 31, 2016 | ($2.52M) | Mar 7, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($95.39M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($141.45M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($105.96M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($80.02M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($32.87M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($6.45M) | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | ($4.96M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($6.66M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($11.95M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($14.96M) | Feb 6, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.59M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $69.64M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $89.42M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $68.03M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $24.81M | Feb 28, 2024 |
| FY2018 | Dec 31, 2018 | $2.97M | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | $7.62M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $9.18M | Feb 6, 2018 |
| FY2016 | Dec 31, 2015 | $9.10M | Mar 7, 2017 |
| FY2016 | Dec 31, 2014 | $7.31M | Mar 7, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($32.25M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($116.93M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($82.03M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($77.51M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($30.20M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($5.38M) | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | ($2.51M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($4.77M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($8.24M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($12.23M) | Feb 6, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $581.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $103.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $414.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $2.71M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $22.21M | Feb 28, 2024 |
| FY2020 | Dec 31, 2019 | $18.0K | Mar 23, 2021 |
| FY2017 | Dec 31, 2016 | $75.0K | Feb 6, 2018 |
| FY2016 | Dec 31, 2015 | $195.0K | Mar 7, 2017 |
| FY2016 | Dec 31, 2014 | $80.0K | Mar 7, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.36M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $157.53M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $151.66M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $234.83M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $266.78M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $94.30M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $23.49M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $20.14M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $10.83M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $19.30M | Feb 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.95M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $11.83M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $14.20M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $7.30M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $12.87M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.10M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.39M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $511.0K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $1.13M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $665.0K | Feb 6, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.40M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $145.70M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $137.47M | Mar 12, 2026 |
| FY2025 | Dec 31, 2022 | $227.54M | Mar 12, 2026 |
| FY2024 | Dec 31, 2021 | $253.92M | Mar 3, 2025 |
| FY2023 | Dec 31, 2020 | $92.20M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $22.10M | Feb 28, 2023 |
| FY2020 | Dec 31, 2018 | $19.63M | Mar 23, 2021 |
| FY2019 | Dec 31, 2017 | $9.70M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $18.64M | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($496.08M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($405.11M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($380.77M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($283.55M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($207.31M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($174.92M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($168.59M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($163.96M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($157.40M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($145.49M) | Feb 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.50M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $128.57M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $121.14M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $201.02M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $233.44M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $93.51M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $23.08M | Mar 23, 2021 |
| FY2020 | Dec 31, 2018 | $19.81M | Mar 23, 2021 |
| FY2019 | Dec 31, 2017 | $10.48M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $16.62M | Mar 29, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2015 | Dec 31, 2015 | 0 | Mar 3, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Mar 3, 2016 |
| FY2015 | Dec 31, 2013 | 0 | Mar 3, 2016 |
| FY2015 | Sep 30, 2013 | 0 | Mar 3, 2016 |
| FY2015 | Jun 30, 2013 | 0 | Mar 3, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 3, 2025 |
| FY2015 | Dec 31, 2015 | 0 | Mar 3, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Mar 3, 2016 |
| FY2015 | Dec 31, 2013 | 0 | Mar 3, 2016 |
| FY2015 | Sep 30, 2013 | 0 | Mar 3, 2016 |
| FY2015 | Jun 30, 2013 | 0 | Mar 3, 2016 |
| FY2015 | Mar 31, 2013 | 0 | Mar 3, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48.31M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 48.20M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 42.24M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 41.74M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 40.02M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 35.24M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 21.84M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 17.22M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 6.60M | Mar 29, 2019 |
| FY2017 | May 3, 2017 | 46.10M | Feb 6, 2018 |